Investor optimism has waned as final minutes from uniQure’s pre-BLA meeting with the FDA convey that data from the company’s ...

UniQure shares fell Thursday after the gene therapy company said its Huntington's disease drug hit more regulatory roadblocks. Shares of the Lexington, Mass., company fell 15% early Thursday, to ...

UniQure stock plunged, again, Thursday after the FDA said it doesn't have enough evidence for a Huntington's approval.

October meeting with the FDA confirm the agency doesn't see the data collected so far as enough to support an approval filing ...

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130. High-dose patients had 75% less progression over three years compared with standard care. uniQure ...

A new, one-time treatment could be the answer to cure Huntington's disease, a neurodegenerative disease long-considered untreatable. Although results are promising, approval for the treatment is ...

Scientists have achieved first-ever successful treatment for one of the most devastating genetic diseases, Huntington’s in a recent medical breakthrough. In the pivotal research study, the team of ...

Scientists have slowed the progression of Huntington’s disease for the first time with a “groundbreaking” new treatment. Experts from University College London (UCL) said the finding could “change ...

Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen approximately twenty years before a clinical motor diagnosis in people with Huntington’s ...

The successful gene therapy is AMT-130, developed by a company called UniQure. In a three-year trial of 29 participants with ...

Dear Doctor: My husband was recently diagnosed with Huntington’s chorea. Is this the same thing as Huntington’s disease? We would like to know what we can expect in the future with this condition. Are ...